---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116254"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:06:02.099304+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Nasdaq delisting risk: MVLS below $35M minimum

## Summary
- Received Nasdaq deficiency notice on Nov 6, 2023 for MVLS below $35M required for continued listing.
- Has 180 calendar days, until May 6, 2024, to regain compliance; must close at $35M+ for 10 consecutive days.
- Common stock continues trading under symbol BCLI on Nasdaq Capital Market during compliance period.
- Company intends to take reasonable measures to regain compliance but no assurance of success.
- If not compliant by May 6, 2024, Nasdaq may delist; appeal possible but uncertain.

## SEC filing metadata
- accession: 0001104659-23-116254
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/0001104659-23-116254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/tm2330353d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116254
- JSON: https://secwatch.observer/filing/0001104659-23-116254.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116254.txt

## Key facts
- Listing & Compliance Notices
  BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: November 6, 2023, Brainstorm Cell Therapeutics Inc. (the “Company”) received a letter (the “MVLS Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that from September 25, 2023 to November 3, 2023, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The MVLS Deficiency Notice has no immediate effect on the listing of the Company’s comm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/0001104659-23-116254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.